DK1299103T3 - 4,5-dihydro-thiazol-2-ylamin og deres anvendelse som inhibitorer for NO-synthase - Google Patents

4,5-dihydro-thiazol-2-ylamin og deres anvendelse som inhibitorer for NO-synthase

Info

Publication number
DK1299103T3
DK1299103T3 DK01943579T DK01943579T DK1299103T3 DK 1299103 T3 DK1299103 T3 DK 1299103T3 DK 01943579 T DK01943579 T DK 01943579T DK 01943579 T DK01943579 T DK 01943579T DK 1299103 T3 DK1299103 T3 DK 1299103T3
Authority
DK
Denmark
Prior art keywords
ylamine
thiazol
dihydro
synthase inhibitors
synthase
Prior art date
Application number
DK01943579T
Other languages
Danish (da)
English (en)
Inventor
Eric Bacque
Serge Mignani
Antony Bigot
Jean-Christophe Carry
Dominique Damour
Claude Guyon
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Application granted granted Critical
Publication of DK1299103T3 publication Critical patent/DK1299103T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/18—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
DK01943579T 2000-06-09 2001-06-07 4,5-dihydro-thiazol-2-ylamin og deres anvendelse som inhibitorer for NO-synthase DK1299103T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0007396A FR2810036B1 (fr) 2000-06-09 2000-06-09 Derives de 4,5-dihydro-1,3-thiazol-2-ylamine, leur preparation et les compositions phamarceutiques les contenant

Publications (1)

Publication Number Publication Date
DK1299103T3 true DK1299103T3 (da) 2006-01-23

Family

ID=8851133

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01943579T DK1299103T3 (da) 2000-06-09 2001-06-07 4,5-dihydro-thiazol-2-ylamin og deres anvendelse som inhibitorer for NO-synthase

Country Status (27)

Country Link
EP (1) EP1299103B1 (es)
JP (1) JP4171297B2 (es)
KR (1) KR20030017990A (es)
CN (1) CN1441673A (es)
AP (1) AP2002002707A0 (es)
AT (1) ATE305298T1 (es)
AU (2) AU2001266123B2 (es)
BR (1) BR0111543A (es)
CA (1) CA2411572C (es)
DE (1) DE60113686T2 (es)
DK (1) DK1299103T3 (es)
DZ (1) DZ3366A1 (es)
EA (1) EA200300009A1 (es)
EC (1) ECSP024374A (es)
ES (1) ES2246327T3 (es)
FR (1) FR2810036B1 (es)
HR (1) HRP20020971A2 (es)
HU (1) HUP0300996A3 (es)
IL (1) IL153327A0 (es)
MA (1) MA25815A1 (es)
MX (1) MXPA02012072A (es)
NO (1) NO20025885L (es)
NZ (1) NZ522967A (es)
OA (1) OA12285A (es)
PL (1) PL360282A1 (es)
WO (1) WO2001093867A1 (es)
ZA (1) ZA200209770B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005063732A1 (en) * 2003-12-23 2005-07-14 Microbia, Inc. Compounds and methods for the treatment of asthma

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL107771A0 (en) * 1992-11-27 1994-02-27 Wellcome Found Pharmaceutical compositions containing isothiourea derivatives certain such novel compounds and their preparation
EP0724570B1 (en) * 1993-10-21 1999-03-03 G.D. Searle & Co. Amidino derivatives useful as nitric oxide synthase inhibitors
WO1996014842A1 (en) * 1994-11-15 1996-05-23 Merck & Co., Inc. Substituted heterocycles as inhibitors of nitric oxide synthase

Also Published As

Publication number Publication date
NO20025885L (no) 2003-01-29
JP2003535135A (ja) 2003-11-25
ECSP024374A (es) 2003-02-06
FR2810036A1 (fr) 2001-12-14
DE60113686T2 (de) 2006-07-13
EP1299103B1 (fr) 2005-09-28
AU2001266123B2 (en) 2007-01-25
IL153327A0 (en) 2003-07-06
ES2246327T3 (es) 2006-02-16
AP2002002707A0 (en) 2002-12-31
MA25815A1 (fr) 2003-07-01
MXPA02012072A (es) 2004-08-19
AU6612301A (en) 2001-12-17
HUP0300996A3 (en) 2006-02-28
EA200300009A1 (ru) 2003-04-24
DE60113686D1 (de) 2006-02-09
CA2411572C (fr) 2009-11-10
BR0111543A (pt) 2003-07-01
CA2411572A1 (fr) 2001-12-13
HRP20020971A2 (en) 2005-02-28
ATE305298T1 (de) 2005-10-15
JP4171297B2 (ja) 2008-10-22
EP1299103A1 (fr) 2003-04-09
NO20025885D0 (no) 2002-12-06
CN1441673A (zh) 2003-09-10
PL360282A1 (en) 2004-09-06
NZ522967A (en) 2005-07-29
FR2810036B1 (fr) 2004-04-23
ZA200209770B (en) 2004-03-02
WO2001093867A1 (fr) 2001-12-13
DZ3366A1 (fr) 2001-12-13
KR20030017990A (ko) 2003-03-04
HUP0300996A2 (hu) 2003-08-28
OA12285A (en) 2006-05-12

Similar Documents

Publication Publication Date Title
NO20026010D0 (no) Substituerte quinazolinderivater og deres anvendelse som inhibitorer
DK1268431T3 (da) 3-Cyanoquinoliner, 3-cyano-1,6-naphthyridiner og 3-cyano-1,7-naphthyridiner som proteinkinaseinhibitorer
NO20021239L (no) Pteridinoner som kinase-inhibitorer
DK1140840T3 (da) omega-carboxyaryl-substituerede diphenylurinstoffer som raf-kinase-inhibitorer
DK1498413T3 (da) 4-aminopicolinater og deres anvendelse som herbicider
DK1220831T3 (da) Biaryletherderivater, der er nyttige som monoamingenoptagelsesinhibitorer
DK1373224T3 (da) Nye spirotricykliske derivater og deres anvendelse som phosphodiesterase 7 inhibitorer
NO20023828L (no) Pyrimidin-4-on derivater som LDL-PLA2 inhibitorer
DK1480962T3 (da) 5-Phenylthiazol-derivater og deres anvendelse som P1-3-kinaseinhibitorer
ATE524441T1 (de) Vla-4-inhibitoren
NO20015065D0 (no) Pyrazolobenzodiazepiner som CDK2-inhibitorer
NO20053356L (no) Aminindazolderivater og anvendelse derav som kinaseinhibitorer.
NO20024997D0 (no) 2-guanidino-4-arylkinazoliner som NHE-3-inhibitorer
EP1328647A4 (en) ISOMALTULOSE SYNTHASE
FI20002044A0 (fi) Comt-entsyymiä estäviä naftaleenijohdannaisia
NO20026164D0 (no) Benzoksazepinoner og deres anvendelse som squalen syntase inhibitorer
NO20030813L (no) Bifenylderivater og deres anvendelse som integrininhibitorer
DK1214302T3 (da) Substituerede 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-oner og deres anvendelse som lipasehæmmere
NO20030243D0 (no) Nye forbindelser og deres anvendelse som glysintransportinhibitorer
NO20023893L (no) Aminosyreforbindelser og deres anvendelse som NEP-, ACE- og ECE-inhibitorer
NO20025884D0 (no) 2-aminotiazolinderivater og deres anvendelse som NO- syntaseinhibitorer
DK1299103T3 (da) 4,5-dihydro-thiazol-2-ylamin og deres anvendelse som inhibitorer for NO-synthase
DK1487802T3 (da) 2,3-diaryl-pyrazolidin-derivater som neurotensin-nedbrydende enzyminhibitorer
DK1115708T3 (da) Aminoalkyl-3,4-dihydriquinolinderivater som NO-synthaseinhibitorer
DK1324980T3 (da) Citrullimyciner, og fremgangsmåde til deres fremstilling og deres anvendelse som lægemidler